ISDA

Entry Detail

PDB ID:

6O8I

Keywords:

TRANSFERASE/INHIBITOR

Title:

BTK In Complex With Inhibitor

Biological Source:

Source Organism:

Homo sapiens

PDB Version:

Deposition Date:

2019-03-11

Release Date:

2019-04-03

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.42 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase BTK
Chain IDs:A
Chain Length:269
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

LTJ

Primary Citation

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).

Watterson, S.H, Liu, Q, Beaudoin Bertrand, M, Batt, D.G, Li, L, Pattoli, M.A, Skala, S, Cheng, L, Obermeier, M.T, Moore, R, Yang, Z, Vickery, R, Elzinga, P.A, Discenza, L, D'Arienzo, C, Gillooly, K.M, Taylor, T.L, Pulicicchio, C, Zhang, Y, Heimrich, E, McIntyre, K.W, Ruan, Q, Westhouse, R.A, Catlett, I.M, Zheng, N, Chaudhry, C, Dai, J, Galella, M.A, Tebben, A.J, Pokross, M, Li, J, Zhao, R, Smith, D, Rampulla, R, Allentoff, A, Wallace, M.A, Mathur, A, Salter-Cid, L, Macor, J.E, Carter, P.H, Fura, A, Burke, J.R, Tino, J.A.Show

J. Med. Chem. 62 3228 3250 (2019)

PMID: 30893553 DOI: 10.1021/acs.jmedchem.9b00167

Abstact

Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures